Stereoselective and nonstereoselective pharmacokinetics of rabeprazole – an overview

References

• Abelö A, Andersson TB, Antonsson M, et al. (2000). Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 28:966–72
   PubMed Web of Science ®Google Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, et al. (2001). Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 40:411–26
   PubMed Web of Science ®Google Scholar
• Andersson T, Weidolf L. (2008). Stereoselective disposition of proton pump inhibitors. Clin Drug Investig 28:263–79
   PubMed Web of Science ®Google Scholar
• Arai K, Takeuchi Y, Watanabe H, et al. (2008). Prokinetics influence the pharmacokinetics of rabeprazole. Digestion 78:67–71
   PubMed Web of Science ®Google Scholar
• Chen ZY, Xie HT, Zheng QS, et al. (2006). Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method. Eur J Drug Metab Pharmacokinet 31:27–33
   PubMed Web of Science ®Google Scholar
• Emerson CR, Marzella N. (2010). Dexlansoprazole: a proton pump inhibitor with a dual delayed-release system. Clin Ther 32:1578–96
   PubMed Web of Science ®Google Scholar
• Friedlander EA, Pallentino J, Miller SK, et al. (2010). The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease. J Am Acad Nurse Pract 22:674–83
   PubMed Web of Science ®Google Scholar
• Fuhr U, Jetter A. (2002). Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 57:595–601
   PubMed Web of Science ®Google Scholar
• Goh KL, Chang CS, Fock KM, et al. (2000). Gastro-oesophageal reflux disease in Asia. J Gastroenterol Hepatol 15:230–8
   PubMed Web of Science ®Google Scholar
• Horn J. (2006). Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors – focus on pKa and metabolism. Aliment Pharmacol Ther Symp Ser 2:340–50
   Google Scholar
• Humphries T, Nardi RV, Spera AC, et al. (1996c). Coadministration of rabeprazole sodium (E381O) does not affect the pharmacokinetics of anhydrous theophylline or warfarin. Gastroenterology 110:A138
   Web of Science ®Google Scholar
• Humphries T, Spera AC, Laurent AL, et al. (1996a). Coadministration of rabeprazole sodium (E3810) and digoxin results in a predictable interaction. Am J Gastroenterology 91:1914
   Google Scholar
• Humphries T, Spera AC, Laurent AL, et al. (1996b). Rabeprazcle sodium (E381O) 20 mg daily does not affect the pharmacokinetics of phenytoin sodium in normal volunteers. Am J Gastroenterology 91:1914
   Google Scholar
• Humphries TJ, Nardi RV, Spera AC, et al. (1996d). Coadministration of rabeprazole sodium (E381O) and ketoconazole results in a predictable interaction with ketoconazole. Gastroenterology 110:AI38
   Web of Science ®Google Scholar
• Ieiri I, Kishimoto Y, Okochi H, et al. (2001). Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol 57:485–92
   PubMed Web of Science ®Google Scholar
• Ishizaki T, Horai Y. (1999). Review article: cytochrome P450 and the metabolism of proton pump inhibitors – emphasis on rabeprazole. Aliment Pharmacol Ther 13: 27–36
   PubMed Web of Science ®Google Scholar
• Itagaki F, Homma M, Yuzawa K, et al. (2004). Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol 56:1055–9
   PubMed Web of Science ®Google Scholar
• Klotz U. (2009). Proton pump inhibitors-their pharmacological impact on the clinical management of acid-related disorders. Arzneimittelforschung 59:271–82
   PubMed Web of Science ®Google Scholar
• Lassen AT. (2007). Acid-related disorders and use of antisecretory medication. Dan Med Bull 54:18–30
   PubMed Web of Science ®Google Scholar
• Li XQ, Andersson TB, Ahlström M, et al. (2004). Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32:821–7
   PubMed Web of Science ®Google Scholar
• Liu G, Wen J, Guo D, et al. (2016). The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. J Pharmacol Sci 132:244–8
   PubMed Web of Science ®Google Scholar
• Malhi V, Colburn D, Williams SJ, et al. (2016). A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib. Cancer Chemother Pharmacol 78:41–9
   PubMed Web of Science ®Google Scholar
• Martin de Argila C. (2005). Safety of potent gastric acid inhibition. Drugs 65:97–104
   PubMed Web of Science ®Google Scholar
• McColl KE, Kennerley P. (2002). Proton pump inhibitors-differences emerge in hepatic metabolism. Dig Liver Dis 34:461–7
   PubMedGoogle Scholar
• Miura M. (2006). Enantioselective disposition of lansoprazole and rabeprazole in human plasma. Yakugaku Zasshi 126:395–402
   PubMed Web of Science ®Google Scholar
• Miura M, Kagaya H, Tada H, et al. (2005). Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. Xenobiotica 35:479–86
   PubMed Web of Science ®Google Scholar
• Miura M, Kagaya H, Tada H, et al. (2006a). Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. Br J Clin Pharmacol 61:315–20
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Inoue K, et al. (2008). Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit 30:46–51
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Tada H, et al. (2006b). Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes. Eur J Clin Pharmacol 62:113–7
   PubMed Web of Science ®Google Scholar
• Musib L, Choo E, Deng Y, et al. (2013). Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. Mol Pharm 10:4046–54
   PubMed Web of Science ®Google Scholar
• Olbe L, Carlsson E, Lindberg P. (2003). A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2:132–9
   PubMed Web of Science ®Google Scholar
• Pichard-Garcia L, Whomsley R, Daujat M, et al. (2000). Comparative effects of rabeprazole and omeprazole on the inducibility of cytochrome P450-1A and cytochrome P450-3A isoenzymes in human hepatocytes, and effects on cyclosporin metabolism in human liver microsomes. Clin Drug Invest 20:245–54
   Web of Science ®Google Scholar
• Qiao HL, Hu YR, Tian X, et al. (2006). Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol 62:107–12
   PubMed Web of Science ®Google Scholar
• Ren S, Park MJ, Kim A, et al. (2008). In vitro metabolic stability of moisture-sensitive rabeprazole in human liver microsomes and its modulation by pharmaceutical excipients. Arch Pharm Res 31:406–13
   PubMed Web of Science ®Google Scholar
• Robinson M, Horn J. (2003). Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 63:2739–54
   PubMed Web of Science ®Google Scholar
• Ruiz-Garcia A, Masters JC, Mendes da Costa L, et al. (2016). Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers. J Clin Pharmacol 56:223–30
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Howden CW. (2006). Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 23:2–8
   PubMed Web of Science ®Google Scholar
• Setoyama T, Drijfhout WJ, van de Merbel NC, et al. (2006). Mass balance study of [14C] rabeprazole following oral administration in healthy subjects. Int J Clin Pharmacol Ther 44:557–65
   PubMed Web of Science ®Google Scholar
• Shao F, Sun J, Wang G, et al. (2007). Liquid chromatographic-mass spectrometry analysis and pharmacokinetic studies of a novel rabeprazole formulation, sterile powder for injection, in dogs and rats. Biopharm Drug Dispos 28:177–86
   PubMed Web of Science ®Google Scholar
• Sheng YC, Wang K, He YC, et al. (2010). Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers. Eur J Clin Pharmacol 66:1165–9
   PubMed Web of Science ®Google Scholar
• Shimizu M, Uno T, Yasui-Furukori N, et al. (2006). Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol 62:597–603
   PubMed Web of Science ®Google Scholar
• Srinivas NR. (2010). Clinical pharmacology of primary metabolites that exhibit genetic polymorphic disposition – case studies of pactimibe, rupatidine and rabeprazole. In: Srinivas NR, ed. Drug development perspectives: considerations, challenges and perspectives. HNB Publishing: New York
   Google Scholar
• Treiber G, Malfertheiner P, Klotz U. (2007). Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. Expert Opin Pharmacother 8:329–50
   PubMed Web of Science ®Google Scholar
• Uno T, Shimizu M, Yasui-Furukori N, et al. (2006). Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol 61:309–14
   PubMed Web of Science ®Google Scholar
• Uno T, Niioka T, Hayakari M, et al (2007). Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. Eur J Clin Pharmacol 63:143–9
   PubMed Web of Science ®Google Scholar
• Vakily M, Zhang W, Wu J, et al. (2009). Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 25:627–38
   PubMed Web of Science ®Google Scholar
• Ware JA, Dalziel G, Jin JY, et al. (2013). Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility. Mol Pharm 10:4074–81
   PubMed Web of Science ®Google Scholar
• Wu J, Jia LT, Shao LM, et al. (2013). Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers. Eur J Clin Pharmacol 69:179–87
   PubMed Web of Science ®Google Scholar
• Yacyshyn BR, Thomson AB. (2002). The clinical importance of proton pump inhibitor pharmacokinetics. Digestion 66:67–78
   PubMed Web of Science ®Google Scholar
• Yasuda S, Higashi S, Murakami M, et al. (1999). Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers. Int J Clin Pharmacol Ther 37:249–53
   PubMed Web of Science ®Google Scholar
• Yasuda S, Ohnishi A, Ogawa T, et al. (1994). Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 32:466–73
   PubMed Web of Science ®Google Scholar